Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Martensson 2003 TZA (Continued)<br />
Allocation concealment? No None described<br />
Blinding?<br />
All outcomes<br />
Incomplete outcome data addressed?<br />
All outcomes<br />
No No blinding is described. 10% of malaria<br />
films were cross-checked by an independaent<br />
examiner in a central laboratory<br />
Yes Low losses to follow up (1.5% AL6 vs 1%<br />
AS+AQ)<br />
Free of selective reporting? Yes All WHO outcomes reported<br />
Free of other bias? No Due to different inclusion criteria <strong>for</strong> the 2<br />
groups, participants in the AL6 group were,<br />
on average, older and heavier at baseline<br />
Mayxay 2003 LAO<br />
Methods Trial design: A 3-arm, open label randomized controlled trial<br />
Follow up: Temperature was measured every 6 hours and patient reviewed daily until<br />
fever and parasites cleared then weekly until day 42 or any time they felt unwell. At each<br />
visit a malaria film and haematocrit measurement was taken.<br />
Adverse event monitoring: Potential side effects were recorded at each visit<br />
Participants Number: 220 randomized into included treatment arms<br />
Inclusion criteria: Age > 1 yr, axillary temp > 37.5 ºC or history of fever in previous 3<br />
days, P. falciparum parasitaemia 5000 to 200,000/µl, likely to stay in hospital until fever<br />
cleared and complete 42 days follow up, in<strong>for</strong>med consent<br />
Exclusion criteria: Pregnancy or lactation, signs of severe malaria, history of allergy or<br />
contraindication to the study drugs, a full course of antimalarials in the previous 3 days<br />
Interventions 1. Artemether-lumefantrine, fixed dose <strong>combination</strong>, 20 mg/120 mg tablets (Coartem:<br />
Novartis)<br />
• < 15 kg 1 tablet twice daily <strong>for</strong> 3 days<br />
• 15 to 24 kg 2 tablets twice daily <strong>for</strong> 3 days<br />
• 25 to 34 kg 3 tablets twice daily <strong>for</strong> 3 days<br />
• > 35 kg 4 tablets twice daily <strong>for</strong> 3 days<br />
• Advised to take with fatty food<br />
2. Artesunate plus mefloquine, loose <strong>combination</strong> (artesunate: Guilan, Lariam: Roche)<br />
• AS 4 mg/kg once daily <strong>for</strong> 3 days<br />
• MQ 15 mg/kg on day 1 and 10 mg/kg on day 2<br />
All doses supervized<br />
Outcomes 1. Cure rates at day 42, PCR adjusted and unadjusted<br />
2. P. vivax parasitaemia during follow up<br />
3. Gametocyte development<br />
4. Mean haematocrit after treatment<br />
5. Adverse events<br />
Not included in the review:<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
76